Search Results - "FETTING, John"

GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas by Cimino-Mathews, Ashley, MD, Subhawong, Andrea P., MD, Illei, Peter B., MD, Sharma, Rajni, PhD, Halushka, Marc K., MD, PhD, Vang, Russell, MD, Fetting, John H., MD, Park, Ben Ho, MD, PhD, Argani, Pedram, MD

“…Summary GATA3 plays an integral role in breast luminal cell differentiation and is implicated in breast cancer progression. GATA3 immunohistochemistry is a…”
Get full text

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study by Connolly, Roisin M, Li, Huili, Jankowitz, Rachel C, Zhang, Zhe, Rudek, Michelle A, Jeter, Stacie C, Slater, Shannon A, Powers, Penny, Wolff, Antonio C, Fetting, John H, Brufsky, Adam, Piekarz, Richard, Ahuja, Nita, Laird, Peter W, Shen, Hui, Weisenberger, Daniel J, Cope, Leslie, Herman, James G, Somlo, George, Garcia, Agustin A, Jones, Peter A, Baylin, Stephen B, Davidson, Nancy E, Zahnow, Cynthia A, Stearns, Vered

“…In breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor led to reexpression of genes…”
Get full text

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group by Tevaarwerk, Amye J, Wang, Molin, Zhao, Fengmin, Fetting, John H, Cella, David, Wagner, Lynne I, Martino, Silvana, Ingle, James N, Sparano, Joseph A, Solin, Lawrence J, Wood, William C, Robert, Nicholas J

“…The effects of ovarian function suppression (OFS) on survival and patient-reported outcomes were evaluated in a phase III trial in which premenopausal women…”
Get full text

Survival in Patients With Metastatic Recurrent Breast Cancer After Adjuvant Chemotherapy: Little Evidence of Improvement Over the Past 30 Years by TEVAARWERK, Amye J, GRAY, Robert J, SCHNEIDER, Bryan P, LOU SMITH, Mary, WAGNER, Lynne I, FETTING, John H, DAVIDSON, Nancy, GOLDSTEIN, Lori J, MILLER, Kathy D, SPARANO, Joseph A

“…Population-based studies have shown improved survival for patients diagnosed with metastatic breast cancer over time, presumably because of the availability of…”
Get full text

Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation by Emens, Leisha A, Asquith, Justin M, Leatherman, James M, Kobrin, Barry J, Petrik, Silvia, Laiko, Marina, Levi, Joy, Daphtary, Maithili M, Biedrzycki, Barbara, Wolff, Antonio C, Stearns, Vered, Disis, Mary L, Ye, Xiaobu, Piantadosi, Steven, Fetting, John H, Davidson, Nancy E, Jaffee, Elizabeth M

“…Granulocyte-macrophage colony-stimulating factor (GM-CSF) -secreting tumor vaccines have demonstrated bioactivity but may be limited by disease burdens and…”
Get full text

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood by HIGGINS, Michaela J, JELOVAC, Danijela, EMENS, Leisha, RILEY, Carol, STEARNS, Vered, DIEHL, Frank, ANGENENDT, Philipp, PENG HUANG, COPE, Leslie, ARGANI, Pedram, MURPHY, Kathleen M, BACHMAN, Kurtis E, BARNATHAN, Evan, GRESHOCK, Joel, WOLFF, Antonio C, PARK, Ben H, BLAIR, Brian, SLATER, Shannon, POWERS, Penny, ZORZI, Jane, JETER, Stacie C, OLIVER, George R, FETTING, John

“…We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer…”
Get full text

MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors by Singhi, Aatur D, Cimino-Mathews, Ashley, Jenkins, Robert B, Lan, Fusheng, Fink, Stephanie R, Nassar, Hind, Vang, Russell, Fetting, John H, Hicks, Jessica, Sukumar, Saraswati, De Marzo, Angelo M, Argani, Pedram

“…In breast cancer, amplification of MYC is consistently observed in aggressive forms of disease and correlates with poor prognosis and distant metastases…”
Get full text

Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer by Kim, Hyun-Seok, Umbricht, Christopher B, Illei, Peter B, Cimino-Mathews, Ashley, Cho, Soonweng, Chowdhury, Nivedita, Figueroa-Magalhaes, Maria Cristina, Pesce, Catherine, Jeter, Stacie C, Mylander, Charles, Rosman, Martin, Tafra, Lorraine, Turner, Bradley M, Hicks, David G, Jensen, Tyler A, Miller, Dylan V, Armstrong, Deborah K, Connolly, Roisin M, Fetting, John H, Miller, Robert S, Park, Ben Ho, Stearns, Vered, Visvanathan, Kala, Wolff, Antonio C, Cope, Leslie

“…Purpose Gene expression profiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor-positive, lymph node-negative breast…”
Get full text

Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy by Cimino-Mathews, Ashley, MD, Hicks, Jessica L., MS, Illei, Peter B., MD, Halushka, Marc K., MD, PhD, Fetting, John H., MD, De Marzo, Angelo M., MD, PhD, Park, Ben Ho, MD, PhD, Argani, Pedram, MD

“…Summary Androgen receptor (AR) is expressed in approximately 70% of primary breast carcinomas (PBCs) and is a promising therapeutic target for metastatic…”
Get full text

Sharing in care: engaging care partners in the care and communication of breast cancer patients by Wolff, Jennifer L., Aufill, Jennifer, Echavarria, Diane, Heughan, JaAlah-Ai, Lee, Kimberley T., Connolly, Roisin M., Fetting, John H., Jelovac, Danijela, Papathakis, Katie, Riley, Carol, Stearns, Vered, Thorner, Elissa, Zafman, Nelli, Levy, Howard P., Dy, Sydney M., Wolff, Antonio C.

“…Purpose Family is often overlooked in cancer care. We developed a patient–family agenda setting intervention to engage family in cancer care communication…”
Get full text

Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases by WU, Julie M, FACKLER, Mary Jo, HICKS, Jessica L, CHITALE, Dhananjay, LADANYI, Marc, SUKUMAR, Saraswati, ARGANI, Pedram, HALUSHKA, Marc K, MOLAVI, Diana W, TAYLOR, M. Evangeline, WEI WEN TEO, GRIFFIN, Constance, FETTING, John, DAVIDSON, Nancy E, DE MARZO, Angelo M

“…Purpose: A comprehensive comparison of biomarker expression between patients' primary breast carcinoma (PBC) and their metastatic breast carcinomas (MBC) has…”
Get full text

A randomized intervention involving family to improve communication in breast cancer care by Wolff, Jennifer L., Aufill, Jennifer, Echavarria, Diane, Blackford, Amanda L., Connolly, Roisin M., Fetting, John H., Jelovac, Danijela, Papathakis, Katie, Riley, Carol, Stearns, Vered, Zafman, Nelli, Thorner, Elissa, Levy, Howard P., Guo, Amy, Dy, Sydney M., Wolff, Antonio C.

“…We examined the effects of a communication intervention to engage family care partners on patient portal (MyChart) use, illness understanding, satisfaction…”
Get full text

Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk by Visvanathan, Kala, Cimino-Mathews, Ashley, Fackler, Mary Jo, Karia, Pritesh S., VandenBussche, Christopher J., Orellana, Mikiaila, May, Betty, White, Marissa J., Habibi, Mehran, Lange, Julie, Euhus, David, Stearns, Vered, Fetting, John, Camp, Melissa, Jacobs, Lisa, Sukumar, Saraswati

“…Introduction. Critical regulatory genes are functionally silenced by DNA hypermethylation in breast cancer and premalignant lesions. The objective of this…”
Get full text

Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach by Sheng, Jennifer Y, Santa-Maria, Cesar A, Mangini, Neha, Norman, Haval, Couzi, Rima, Nunes, Raquel, Wilkinson, Mary, Visvanathan, Kala, Connolly, Roisin M, Roussos Torres, Evanthia T, Fetting, John H, Armstrong, Deborah K, Tao, Jessica J, Jacobs, Lisa, Wright, Jean L, Thorner, Elissa D, Hodgdon, Christine, Horn, Samantha, Wolff, Antonio C, Stearns, Vered, Smith, Karen L

“…The COVID-19 pandemic has rapidly changed delivery of cancer care. Many nonurgent surgeries are delayed to preserve hospital resources, and patient visits to…”
Get more information

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial by Santa-Maria, Cesar A., Bardia, Aditya, Blackford, Amanda L., Snyder, Claire, Connolly, Roisin M., Fetting, John H., Hayes, Daniel F., Jeter, Stacie C., Miller, Robert S., Nguyen, Anne, Quinlan, Katie, Rosner, Gary L., Slater, Shannon, Storniolo, Anna Maria, Wolff, Antonio C., Zorzi, Jane, Henry, Nora Lynn, Stearns, Vered

“…Purpose Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a…”
Get full text

Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation by Smith, Karen Lisa, Verma, Neha, Blackford, Amanda L., Lehman, Jennifer, Westbrook, Kelly, Lim, David, Fetting, John, Wolff, Antonio C., Jelovac, Daniela, Miller, Robert S., Connolly, Roisin, Armstrong, Deborah K., Nunes, Raquel, Visvanathan, Kala, Riley, Carol, Papathakis, Katie, Zafman, Nelli, Sheng, Jennifer Y., Snyder, Claire, Stearns, Vered

“…Many patients discontinue endocrine therapy for breast cancer due to intolerance. Identification of patients at risk for discontinuation is challenging. The…”
Get full text

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer by Chen, Gang, Gupta, Richa, Petrik, Silvia, Laiko, Marina, Leatherman, James M, Asquith, Justin M, Daphtary, Maithili M, Garrett-Mayer, Elizabeth, Davidson, Nancy E, Hirt, Kellie, Berg, Maureen, Uram, Jennifer N, Dauses, Tianna, Fetting, John, Duus, Elizabeth M, Atay-Rosenthal, Saadet, Ye, Xiaobu, Wolff, Antonio C, Stearns, Vered, Jaffee, Elizabeth M, Emens, Leisha A

“…Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines are bioactive, but limited by disease burden and immune tolerance…”
Get more information

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer by Higgins, Michaela J., Prowell, Tatiana M., Blackford, Amanda L., Byrne, Celia, Khouri, Nagi F., Slater, Shannon A., Jeter, Stacie C., Armstrong, Deborah K., Davidson, Nancy E., Emens, Leisha A., Fetting, John H., Powers, Pendleton P., Wolff, Antonio C., Green, Hannah, Thibert, Jacklyn N., Rae, James M., Folkerd, Elizabeth, Dowsett, Mitchell, Blumenthal, Roger S., Garber, Judy E., Stearns, Vered

“…Observational studies have demonstrated a decreased incidence of cancers among users of HMG CoA reductase inhibitors (statins) and a reduced risk of recurrence…”
Get full text

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer by Rudek, Michelle A., Connolly, Roisin M., Hoskins, Janelle M., Garrett-Mayer, Elizabeth, Jeter, Stacie C., Armstrong, Deborah K., Fetting, John H., Stearns, Vered, Wright, Laurie A., Zhao, Ming, Watkins, Stanley P., McLeod, Howard L., Davidson, Nancy E., Wolff, Antonio C.

“…The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer. However, toxicity and large…”
Get full text

TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer by Connolly, Roisin M, Leal, Jeffrey P, Goetz, Matthew P, Zhang, Zhe, Zhou, Xian C, Jacobs, Lisa K, Mhlanga, Joyce, O, Joo H, Carpenter, John, Storniolo, Anna Maria, Watkins, Stanley, Fetting, John H, Miller, Robert S, Sideras, Kostandinos, Jeter, Stacie C, Walsh, Bridget, Powers, Penny, Zorzi, Jane, Boughey, Judy C, Davidson, Nancy E, Carey, Lisa A, Wolff, Antonio C, Khouri, Nagi, Gabrielson, Edward, Wahl, Richard L, Stearns, Vered

“…Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a…”
Get full text